title: [Treatment of high myopic choroidal neovascularisation with intravitreal bevacizumab].
abstract: OBJECTIVE
  To evaluate the safety and efficacy of intravitreal bevacizumab (IVB) in the treatment of high myopic choroidal neovascularization (CNV).
  
  
  METHODS
  Retrospective study of 16 eyes of 16 patients with high myopic choroidal neovascularization treated with first-line IVB (1.25mg/0.05mL) with a one-year follow-up. All patients underwent a complete baseline (M0) ophthalmologic examination, including the measurement of best corrected visual acuity (BCVA), biomicroscopic and fundus examination, fluorescein and indocyanine green angiography, and optical coherence tomography. Patients were followed monthly. Additional IVB was administered when persistent or additional retinal exudation was observed. The main study parameters were visual acuity at 1, 6 and 12 months and the progression of exudation on OCT and angiography.
  
  
  RESULTS
  Mean age was 63±14 years and spherical equivalent was -15.4±7.4 diopters. Baseline BCVA was 0.75±0.5 logMAR. Mean follow-up was 15±2 months. The average number of IVB was 2.4±1.2 injections. Metamorphopsia decreased in all patients and completely disappeared in fourteen eyes. Mean BCVA was 0.5±0.3 logMAR at M1 and 0.6±0.5 logMAR at M6 and M12. No adverse events related to the intravitreal injections were observed.
  
  
  CONCLUSIONS
  Our study showed that IVB (Avastin(®)) is effective in the treatment of high myopic CNV. Moreover, only a small number of intravitreal injections were required to treat this condition.
authors.affiliation: Service d'ophtalmologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France.
authors.forename: B
authors.initials: B
authors.lastname: Mathieu
authors.affiliation: Service d'ophtalmologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France.
authors.forename: R
authors.initials: R
authors.lastname: Isaico
authors.affiliation: Service d'ophtalmologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France.
authors.forename: J-C
authors.initials: JC
authors.lastname: Ramel
authors.affiliation: Service d'ophtalmologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France.
authors.forename: A-M
authors.initials: AM
authors.lastname: Bron
authors.affiliation: Service d'ophtalmologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France. Electronic address: catherine.creuzot-garcher@chu-dijon.fr.
authors.forename: C
authors.initials: C
authors.lastname: Creuzot-Garcher
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Anti-VEGF; Bevacizumab; Choroidal neovascularization; Myopia; Myopie; Néovaisseaux; Néovascularisation choroïdienne